03960nam 2200625 450 991078730810332120230801231314.00-309-26119-80-309-26117-1(CKB)2670000000410074(EBL)3379066(SSID)ssj0000746505(PQKBManifestationID)11447835(PQKBTitleCode)TC0000746505(PQKBWorkID)10861620(PQKB)11316072(MiAaPQ)EBC3379066(Au-PeEL)EBL3379066(CaPaEBR)ebr10863714(OCoLC)829421146(EXLCZ)99267000000041007420130212h20122012 uy| 0engurcnu||||||||txtccrMaximizing the impact of the Cures Acceleration Network accelerating the development of new drugs and diagnostics : workshop summary /Steve Olson and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National AcademiesWashington, District of Columbia :National Academies Press,[2012]©20121 online resource (132 p.)Description based upon print version of record.0-309-26116-3 Includes bibliographical references (pages 71).Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science -- Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem -- Final reflections on ways to maximize the goals of CAN.Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description.Drug monitoringDrug developmentUnited StatesDrugsUnited StatesDesignPharmaceutical industryUnited StatesQuality controlDrug monitoring.Drug developmentDrugsDesign.Pharmaceutical industryQuality control.615.1/9Olson Steve1956-Claiborne Anne B.National Institute of Medicine (U.S.).Board on Health Sciences Policy,MiAaPQMiAaPQMiAaPQBOOK9910787308103321Maximizing the impact of the Cures Acceleration Network3829043UNINA